Sachi's NanoligomerTM platform can deliver to the brain with systemic administration
Brain delivery of Nanoligomer using systemic administration What if you could deliver RNA therapeutics to the brain for high-precision...
top of page
Press releases
Oct 1, 2022
Sachi selected for Creative Destruction Lab's 2022-2023 cohort
Sachi Bio has been selected to join the Creative Destruction Labs 2022-2023 cohort alongside 25 ground-breaking companies in the Advanced...
Sep 20, 2022
Sachi Bio receives NIH SBIR award
Sachi Bio wins NIH SBIR award to advance microbiome leads to treat auto-immune diseases. Difficult-to-treat autoimmune diseases that are...
Sep 15, 2022
Sachi Bio selected to join Endless Frontier Labs (EFL) 2022-23 cohort
Sachi Bio has been selected to join the Endless Frontier Labs 2022-2023 cohort alongside 25 ground-breaking companies in the Life...
Aug 2, 2022
Sachi Bio selected in the NASA I-Corps Program
Sachi Bio has been selected in the 2022 cohort of the NASA I-Corps program. The NASA I-Corps program enables small businesses, including...
May 26, 2022
Sachi Bio wins NASA Phase I SBIR award to advance drug-discovery on the ISS
May 26, 2022 Rapid, Low-Cost Drug-Discovery in Space In space exploration missions or space tourism outside the earth’s protective...
May 23, 2022
Sachi founders highlighted in “The Shift” column in the Timmerman Report
Out of the University, and in to Outer Space May 23rd, 2022 The Shift, by Lisa Suennen Lisa Suennen, is the managing founder of Venture...
May 11, 2022
Sachi Bio publishes on immunotherapy drug-development in Life Sciences in Space Research
Reversing radiation-induced immunosuppression using a new therapeutic modality May 11, 2022 Immune suppression poses significant health...
Subscribe to Our Newsletter
Follow Us On:
© 2024 Sachi Bio
bottom of page